Navigation Links
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Date:6/26/2008

Study Meets Primary Endpoint, with Positive Effect Sustained Through

Duration of 4-Week Study

ROCKVILLE, Md., June 26 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) (Vanda) today announced positive top-line results from a Phase III trial showing that its investigational drug candidate, tasimelteon (VEC-162), a novel melatonin agonist, met the primary endpoint of the trial and significantly improved sleep in adult patients with chronic insomnia.

"We are excited that the results of this Phase III chronic insomnia study demonstrate the clinical utility of tasimelteon and the ability of the compound to treat sleep disorders over a period of four weeks. The mechanism of action of tasimelteon as a circadian regulator gives Vanda the opportunity to explore its use for the treatment of circadian rhythm sleep disorders as well as chronic primary insomnia," stated Paolo Baroldi, MD, PhD, Vanda's Chief Medical Officer.

This Phase III, multi-center, placebo-controlled, 4-week trial evaluated 322 patients with chronic primary insomnia. Patients were randomized to receive either 20 mg or 50 mg of tasimelteon or placebo over the course of four weeks. The primary endpoint consisted of the evaluation of the immediate and short-term (average of Nights 1 and 8) ability of tasimelteon to improve sleep onset as measured by Latency to Persistent Sleep (LPS) through polysomnography (PSG). Secondary endpoints evaluated tasimelteon's ability to maintain improvements on sleep onset after long-term (average of Nights 22 and 29) use of the compound as well as measures of sleep duration (Total Sleep Time, TST) and sleep maintenance (Wake After Sleep Onset, WASO). Patients were eligible for the stud
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 Following ... of their transactions, Array BioPharma Inc. (NASDAQ:  ARRY) ... and encorafenib definitive agreements with Novartis.  Along with ... an upfront payment of $85 million from Novartis. ... noted, "With the close of the Novartis-GSK transaction, ...
(Date:3/2/2015)... 2, 2015  The International Myeloma Foundation (IMF), ... myeloma patients while working toward prevention and a ... March to be Myeloma Awareness Month (#MAM). ... Awareness Month in 2009. Throughout the month, the ... community events, social media campaigns, story sharing, and ...
(Date:3/2/2015)... -- Cardinal Health today announced plans to acquire Johnson ... cardiology and endovascular devices, for $1.944 billion in cash, ... of tax benefits. The acquisition is expected to be ... senior unsecured notes and the remainder with existing cash. ... the United States and key non-U.S. countries ...
Breaking Medicine Technology:Array Announces Completion Of Binimetinib And Encorafenib Transactions 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 3Array Announces Completion Of Binimetinib And Encorafenib Transactions 4Array Announces Completion Of Binimetinib And Encorafenib Transactions 5International Myeloma Foundation Declares March "Myeloma Awareness Month" 2International Myeloma Foundation Declares March "Myeloma Awareness Month" 3Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 2Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 3Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 4Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 5Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 6Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 7
... Dec. 8, 2011  RainTree Oncology Services (RainTree Oncology), ... and management services, today announced it has signed ... the nation,s largest privately-owned specialty pharmacy providing medication ... the Company to provide community oncology practices with ...
... 2011   Leatt Corporation (OTC: LEAT.PK), a global ... brace system designed to help prevent potentially devastating injuries ... today that the 2011 Annual Meeting (Meeting) of its ... Thursday, December 22, 2011.  Stockholders of record as of ...
Cached Medicine Technology:RainTree Oncology Services Announces Service Agreement With Diplomat Specialty Pharmacy 2RainTree Oncology Services Announces Service Agreement With Diplomat Specialty Pharmacy 3Leatt Corporation Announces 2011 Annual Shareholders' Meeting 2
(Date:3/2/2015)... 2015 ZoomCare announced today the ... healthcare. Zoom will expand its Portland on-demand neighborhood ... advanced care studios delivering urgent care, primary care, ... care and outpatient surgery. With its new neighborhood ... all healthcare needs outside of hospitalization. , “2015 ...
(Date:3/2/2015)... York (PRWEB) March 02, 2015 ... at Recovery Unplugged™—will be delivering a plenary address ... Perspective on the Art of Healing and Recovery ... (NCAD) and Behavioral Healthcare Executive Summit (BHES).     , ... Mr. Supa’s songs have been recorded by some ...
(Date:3/2/2015)... March 02, 2015 This year, the National ... and will provide opportunities for people across the country to ... help people with MS live their best lives. MS Awareness ... to inspire others to join the Society’s vision of a ... unpredictable, often disabling disease of the central nervous system, interrupts ...
(Date:3/2/2015)... Regulatory Compliance Associates® Inc. (RCA), ... and technical consulting, announces Mr. Seyed Khorashahi has ... , Before joining RCA, Mr. Khorashahi had over ... all aspects of developing safety-critical medical devices. ... Regulatory Compliance Associates Inc., Baxter Healthcare, and Beckman ...
(Date:3/2/2015)... Many mainstream media outlets have run stories ... how much of that news reporting is true? Many ... measles, but whose youngsters later developed autism, will assemble ... comprised of professionals, clinicians, researchers, therapists, advocates, and others. ... questions about the body and childhood health will have ...
Breaking Medicine News(10 mins):Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Growing List of Professionals Gather for World’s Most Comprehensive Autism Conference in Chicago, May 2015 2
... 18, 2008 TAP Pharmaceutical Products Inc. today reported ... new drug TAK-390MR, the first proton pump inhibitor (PPI) ... patients with erosive esophagitis (EE) and in maintenance of ... Disease Week (DDW) annual meeting in San Diego. , ...
... the 2000 census, Americans office workers spend an average ... work stations. Many recent studies on job satisfaction have ... environments, often under artificial light in windowless offices, report ... can employers make office environments more conducive to productivity ...
... 19 Volcano Corporation,(Nasdaq: VOLC ), a ... Optical Coherence Tomography (OCT) products designed,to enhance the ... said today that it will be participating in ... May 20., The presentation by Scott Huennekens, ...
... and progression of prostate cancer have eluded scientists ... have identified a specific gene expression profile of ... future treatments. The findings, published in BioMed Centrals ... that are differentially expressed in certain prostate cancer ...
... CHICAGO, May 19 SmithAmundsen LLC is pleased,to announce ... Chicago office,has been elected partner, effective May 17, 2008., ... Health Care practice group,focusing her work on health care ... Health Care Agencies, involving,the defense of both nursing and ...
... 19 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... rejoined the company in a part-time position ... owned subsidiary of Alexza. Mr.,Williams will have ... Singapore and establishing potential joint ventures in,Singapore. ...
Cached Medicine News:Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 2Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 3Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 4Health News:Greener offices make happier employees 2Health News:Volcano Corporation Presentation at JMP Conference to be Webcast 2Health News:Mapping of prostate cancer genes opens the door to new treatments 2Health News:SmithAmundsen Elects New Partner, Linda F. Newman 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 3
Inquire...
... - Anatomically designed to enhance the chin contour, ... mandible with a high-profile central chin projection. ... entire mandible, this implant provides a high central ... arms. Cleft Chin Implants - Designed with ...
... IEC CL40 and FL40 Centrifuge Series ... and versatility to increase your productivity ... broad array of rotors and accessories ... microplate applications, the IEC CL40 and ...
... Series offers unsurpassed versatility and exceptional ... liter benchtop centrifuge. With its broad ... high-speed centrifugation capabilities, the IEC CL31 ... to meet a variety of sample ...
Medicine Products: